Bluebird Bio (BLUE)

$4.97 +0.23 (4.85%)
Market Cap 48.67M
Revenue (ttm) 83.81M
Net Income (ttm) -240.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -287.22%
Debt to Equity Ratio -2.02
Volume 1,245,100
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 9.79M
Stochastic %K N/A
Beta 0.27
Analysts Hold
Price Target $9.33

Company Profile

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cereb...

Industry: Biotechnology
Sector: Healthcare
Phone: 339 499 9300
Address:
455 Grand Union Boulevard, Somerville, United States
gargoyl
gargoyl Sep. 12 at 5:45 AM
$BLRX $BLUE Gamida Cell Arymid BlackRock PDAC SCD Aphreses Motixafortide APHEXDA Kreos Capital
0 · Reply
gargoyl
gargoyl Sep. 12 at 5:17 AM
$BLRX 🗡️ $BLUE 🤔
1 · Reply
gargoyl
gargoyl Sep. 12 at 5:15 AM
$BLRX ⚔️ $BLUE
0 · Reply
gargoyl
gargoyl Sep. 12 at 5:12 AM
$BLRX ⚔️ $BLUE 🤔
0 · Reply
stu4
stu4 Sep. 8 at 1:05 PM
$AGIO can I lead you to water ???? Sure Will you drink it …obviously not !!! Someone gave you bad info…. Now for the real deal…do some homework on: HIM ….( then come back and post , nonsense ) This brain power and CEO stewardship doesn’t, and never did exist here or at $NTLA $CADL $BLUE $DCPH
0 · Reply
Letsinvest2024
Letsinvest2024 Sep. 5 at 5:24 PM
$BLUE where is my CVR payment?
2 · Reply
Obiwan123
Obiwan123 Aug. 31 at 1:33 PM
$BLUE the company that destroyed its shareholders. mgmt with their nice degrees lacked fiduciary duties and integrity. they really messed up lots of investors but mgmt got away with equity incentive free shares and high salaries.
1 · Reply
bachsong
bachsong Aug. 30 at 1:48 PM
$ULCC IMO... LOOK FOR $ULCC TO HEAD TOWARD $10.00! $FFLY Demise will be greatly accretive to $ULCC Bottom Line propeling SP! ULCC has no interest in buying $FFLY (A GOOD THING!) IMO it will pick out assets to buy AT BARGAIN PRICES! ...the only solution for Low Cost carrier increasing profits will be shrinking capacity ... IMO $FFLY will end up in Liquidation (Chapter 7)... or at best shed assets its assets by liquidating and selling ULCC's many routes, assets and planes to $ULCC and $BLUE at bankruptcy PRICES... Before $FFLY filed Chapter 11, $ULCC already added 20 SPIRIT ROUTES to its existing... and it will likely poach $FFLY ASSETS... ADDING REVENUE at lower costs. IMO THIS NEWS and SPIRIT's DEMISE... will be ACCRETIVE to FRONTIER'S bottom line!
0 · Reply
stu4
stu4 Aug. 30 at 12:59 AM
$CADL not with a narcissist as CEO . Looks at what , Nick Leschly , did do $BLUE ..Blue Bird Bio His bullshit pitted wall st against him. Then, the same at $DCPH , decipher therapeutics A $80 valuation gone to shit over Steve Hoerter and his board of narcissistic yah-hoos , sold for $25 !!! Keep it up TAK , and Manning !!
2 · Reply
Tumble51
Tumble51 Aug. 26 at 2:58 PM
$BEAM $BLUE $CRSP $NTLA $QURE Gee ! I see a true statement hit a nerve Hahaha This is the next Blue Bird Bio
0 · Reply
Latest News on BLUE
bluebird bio Strengthens Leadership Team With New Appointments

Jul 1, 2025, 9:00 AM EDT - 2 months ago

bluebird bio Strengthens Leadership Team With New Appointments

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

Jun 2, 2025, 8:34 AM EDT - 3 months ago

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

CG

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

May 30, 2025, 8:30 AM EDT - 3 months ago

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

CG

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

May 27, 2025, 8:30 AM EDT - 4 months ago

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

May 16, 2025, 4:30 PM EDT - 4 months ago

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

CG

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital

May 14, 2025, 8:52 AM EDT - 4 months ago

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital

CG

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

May 14, 2025, 8:30 AM EDT - 4 months ago

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

CG

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

May 9, 2025, 8:30 AM EDT - 4 months ago

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

May 5, 2025, 4:00 PM EDT - 4 months ago

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

CG

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

Apr 16, 2025, 8:00 AM EDT - 5 months ago

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Mar 31, 2025, 11:24 AM EDT - 6 months ago

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Bluebird bio receives non-binding bid for up to $110.5 million

Mar 28, 2025, 5:43 PM EDT - 6 months ago

Bluebird bio receives non-binding bid for up to $110.5 million

Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update

Mar 28, 2025, 5:06 PM EDT - 6 months ago

Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Mar 28, 2025, 4:15 PM EDT - 6 months ago

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

Mar 13, 2025, 3:43 PM EDT - 6 months ago

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.

Feb 21, 2025, 3:43 PM EST - 7 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.

CG

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Feb 21, 2025, 1:48 PM EST - 7 months ago

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs

Feb 21, 2025, 9:45 AM EST - 7 months ago

bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs

CG

Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch

Feb 21, 2025, 8:04 AM EST - 7 months ago

Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch

CG

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

Feb 21, 2025, 7:30 AM EST - 7 months ago

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

CG

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

Feb 18, 2025, 9:52 AM EST - 7 months ago

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

CVS VRTX

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 8, 2024, 12:30 PM EST - 10 months ago

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Dec 7, 2024, 12:00 PM EST - 10 months ago

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

bluebird bio Announces 1-for-20 Reverse Stock Split

Dec 4, 2024, 4:05 PM EST - 10 months ago

bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

Dec 4, 2024, 8:47 AM EST - 10 months ago

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

FDA investigates risk of blood cancers from bluebird bio's gene therapy

Nov 27, 2024, 11:45 AM EST - 10 months ago

FDA investigates risk of blood cancers from bluebird bio's gene therapy

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

Nov 20, 2024, 8:10 AM EST - 10 months ago

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

AAPL ABBV AGNC AM ARCC ARI AVGO

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

Nov 15, 2024, 2:05 PM EST - 10 months ago

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:06 AM EST - 10 months ago

bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Nov 14, 2024, 7:00 AM EST - 10 months ago

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

Nov 6, 2024, 4:15 PM EST - 11 months ago

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:05 AM EST - 11 months ago

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Bluebird Bio (BLUE) Stock Dips Amid Market Volatility

Oct 8, 2024, 3:53 PM EDT - 1 year ago

Bluebird Bio (BLUE) Stock Dips Amid Market Volatility

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BMY CRSP EDIT EXAS NTLA

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 4, 2024, 4:05 PM EDT - 1 year ago

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Sep 27, 2024, 4:30 PM EDT - 1 year ago

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Bluebird bio to cut 25% of workforce as part of restructuring

Sep 24, 2024, 7:08 AM EDT - 1 year ago

Bluebird bio to cut 25% of workforce as part of restructuring

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

Sep 24, 2024, 7:00 AM EDT - 1 year ago

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Sep 13, 2024, 4:41 PM EDT - 1 year ago

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys

Aug 28, 2024, 8:10 AM EDT - 1 year ago

My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys

AAPL ABBV AGNC AM APLE ARCC ARI

bluebird bio Announces September Investor Events

Aug 28, 2024, 8:00 AM EDT - 1 year ago

bluebird bio Announces September Investor Events

bluebird bio Announces Receipt of Expected Notices from Nasdaq

Aug 23, 2024, 4:05 PM EDT - 1 year ago

bluebird bio Announces Receipt of Expected Notices from Nasdaq

bluebird bio, Inc. (BLUE) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 11:14 AM EDT - 1 year ago

bluebird bio, Inc. (BLUE) Q2 2024 Earnings Call Transcript

gargoyl
gargoyl Sep. 12 at 5:45 AM
$BLRX $BLUE Gamida Cell Arymid BlackRock PDAC SCD Aphreses Motixafortide APHEXDA Kreos Capital
0 · Reply
gargoyl
gargoyl Sep. 12 at 5:17 AM
$BLRX 🗡️ $BLUE 🤔
1 · Reply
gargoyl
gargoyl Sep. 12 at 5:15 AM
$BLRX ⚔️ $BLUE
0 · Reply
gargoyl
gargoyl Sep. 12 at 5:12 AM
$BLRX ⚔️ $BLUE 🤔
0 · Reply
stu4
stu4 Sep. 8 at 1:05 PM
$AGIO can I lead you to water ???? Sure Will you drink it …obviously not !!! Someone gave you bad info…. Now for the real deal…do some homework on: HIM ….( then come back and post , nonsense ) This brain power and CEO stewardship doesn’t, and never did exist here or at $NTLA $CADL $BLUE $DCPH
0 · Reply
Letsinvest2024
Letsinvest2024 Sep. 5 at 5:24 PM
$BLUE where is my CVR payment?
2 · Reply
Obiwan123
Obiwan123 Aug. 31 at 1:33 PM
$BLUE the company that destroyed its shareholders. mgmt with their nice degrees lacked fiduciary duties and integrity. they really messed up lots of investors but mgmt got away with equity incentive free shares and high salaries.
1 · Reply
bachsong
bachsong Aug. 30 at 1:48 PM
$ULCC IMO... LOOK FOR $ULCC TO HEAD TOWARD $10.00! $FFLY Demise will be greatly accretive to $ULCC Bottom Line propeling SP! ULCC has no interest in buying $FFLY (A GOOD THING!) IMO it will pick out assets to buy AT BARGAIN PRICES! ...the only solution for Low Cost carrier increasing profits will be shrinking capacity ... IMO $FFLY will end up in Liquidation (Chapter 7)... or at best shed assets its assets by liquidating and selling ULCC's many routes, assets and planes to $ULCC and $BLUE at bankruptcy PRICES... Before $FFLY filed Chapter 11, $ULCC already added 20 SPIRIT ROUTES to its existing... and it will likely poach $FFLY ASSETS... ADDING REVENUE at lower costs. IMO THIS NEWS and SPIRIT's DEMISE... will be ACCRETIVE to FRONTIER'S bottom line!
0 · Reply
stu4
stu4 Aug. 30 at 12:59 AM
$CADL not with a narcissist as CEO . Looks at what , Nick Leschly , did do $BLUE ..Blue Bird Bio His bullshit pitted wall st against him. Then, the same at $DCPH , decipher therapeutics A $80 valuation gone to shit over Steve Hoerter and his board of narcissistic yah-hoos , sold for $25 !!! Keep it up TAK , and Manning !!
2 · Reply
Tumble51
Tumble51 Aug. 26 at 2:58 PM
$BEAM $BLUE $CRSP $NTLA $QURE Gee ! I see a true statement hit a nerve Hahaha This is the next Blue Bird Bio
0 · Reply
stu4
stu4 Aug. 26 at 10:52 AM
$NTLA. Ahhh you poor thing Trolling am I ???? Hardly , just putting out the truth Want those symbols again ??? $BEAM $NTLA $QURE $BLUE ( now private due to failures) $CRSP @Windytimes ahead , blow smoke up every shareholder’s a$$
0 · Reply
Tumble51
Tumble51 Aug. 22 at 4:58 PM
$BLUE Yes ..I return from Aug 2022 when on its first approval , it fell apart and from $5 I got the fcuk out at $10 and called it a pos !!! It was to all those morons that said different. , including the JPM staff !
0 · Reply
neoda1
neoda1 Aug. 18 at 7:03 PM
$BLUE bye shiitbird
0 · Reply
ScarletXW
ScarletXW Aug. 8 at 1:17 AM
$ADAP wow what I don’t get about this one (or $BLUE bluebird bio for example too) is why they got so little for the approved assets? How can a company get less than it probably spent on the trials on an approved therapy?? Right….?
1 · Reply
Dkll303
Dkll303 Aug. 7 at 12:01 PM
$CADL ..they said that at $BLUE ..did an offering , like here Nothing happened ! JPM said “ buy “ target $11….JPM sold out of it on the buy ! SOLD for 300M …. Careful boy wonder, Batman (TAK) could be just a show
0 · Reply
Tumble51
Tumble51 Aug. 6 at 8:10 PM
$CADL $BLUE sold for that , just saying , haha
1 · Reply
Luckypig
Luckypig Aug. 6 at 12:52 AM
$IOVA I hope that i'm wrong, but I don't see us receiving positive news with ER. Mgmt needs to temporarily increase the treatment price from $560K to whatever the price should be until we are breakeven. Once we are breakeven then lower the treatment price. It does not help anyone if we go out of business like $BLUE. We need to be more like $ABEO, they recently received their FDA approval, they charge $3.1M per one-time treatment and will be profitable by 1qt 2026. At the current rate $IOVA will need to dilute again lowering our share price again and eventually either go bankrupt or be sold for pennies on the $. Again, I hope I'm wrong but the foggy path seems to not be on a healthy path "UNLESS" mgmt changes. All the best to everyone that supports Iovance. GLTA!!!
2 · Reply
Jadek6
Jadek6 Aug. 4 at 12:09 PM
$BLUE $CADL not as yet !
0 · Reply
Dkll303
Dkll303 Aug. 3 at 6:31 PM
$BLUE $CADL $SAVA Did Mary Jane say hello to you , Jade ? ..he did to me , lol
0 · Reply
Jadek6
Jadek6 Aug. 3 at 5:19 PM
$CADL Keep convincing yourself @yogi888, like they did at $BLUE , HAAHAH. OH , SAY HI TO @FreedSage2013 $BLUE was going to $100. Sold for 300M , lol $SAVA to $250 ….Phase3 FAILED
1 · Reply
RUMPOTUS
RUMPOTUS Aug. 3 at 3:53 AM
$BLUE bluefin on $SUI
0 · Reply